Precision Medicine – Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.

it — Tue, 14 Jun 2022 13:53:58 +0000

Paris and Cambridge, MA, June 15th 2022. Tersan Pharmaceuticals Ltd and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Tersan Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer treatment options for patients with advanced & refractory diseases.

Focusing on a cohort of advanced & refractory cancer patients without tractable DNA alterations, the analysis concludes that the AI-transcriptional-based therapeutic recommendation-tool Onco KEM® is feasible and has the potential to identify potential therapeutic options for personalized cancer treatment.

The study included the analysis of 50 patients who had no Molecular Based Treatment Recommendation (MBTR) based on routinely used DNA Targeted Genomic Panel, Using RNA-Seq gene expression profiles and the AI-transcriptional-based therapeutic recommendation tool OncoKEM® developed by Tersan and OmiCure, the study showed that at least 2 targeted therapies were proposed for all patients.

“OmiCure and Ariana, with their RNA-based AI technology, have the potential to significantly improve outcomes for cancer patients who have no alternative therapeutic recommendations using DNA analysis only. We are encouraged by these initial results and look forward to assessing the clinical impact of RNA-based therapeutic recommendations in an upcoming clinical trial” commented Dr Pierre Saintigny, the study Principal Investigator, and Head of translational Medicine at the Centre Leon Bérard Cancer Center.

“I am excited by the opportunity of collaborating with the oncology team at the Centre Leon Bérard, a leading European cancer center”, said Thomas Turcat, OmiCure’s COO. “We remain committed to making a difference for particularly difficult patients with advanced metastatic disease where therapeutic alternatives are few and clinical outcomes are poor”.

More details about the study:

• 50 patients with advanced refractory diseases were included in the PROFILER study (NCT01774409), with no MBTR based on a 90-tumor gene panel. The goal was to show the feasibility of MBTR using the AI-transcriptional-based therapeutic recommendation-tool OncoKEM to guide treatment recommendations.
• Most common diagnoses were breast cancers (21%, of which 63% were TNBC), followed by ovarian cancers (OC, 18%) and soft-tissue sarcomas (STS, 13%)
• All patients had at least 2 proposed treatments (range: 2-9) of targeted therapies among the top 10 ranked drugs in the Onco KEM reports
• Most frequently, proposed drugs among the top 10 were
- o In TNBC: palbociclib, talazoparib, infigratinib;
- o In ovarian cancer: bosutinib, sapanisertib, SAR125844;
- o In soft-tissue sarcomas: ipilimumab, cabozantinib, sapanisertib
• AI-transcriptional-based therapeutic recommendation tool OncoKEM is feasible and has the potential to expand personalized cancer treatment in patients with advanced & refractory diseases without tractable genomic alterations. The clinical relevance assessment is planned in an upcoming clinical trial.

More detailed information by clicking on the following links

The full text of the abstract here or https://meetings.asco.org/abstracts-presentations/212349
The ASCO poster
The ASCO Slides
More information about publications from CLB at ASCO2022 here

Full Press Release PDF

About Tersan Pharmaceuticals Ltd

Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine.

Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012.
Further information is available at www.tersanpharm.com

About OmiCure

OmiCure is a leading European digital health company, that develops and markets explainable AI-based therapeutic decision support software. OmiCure’s range of products provide physicians with the support they need when making complex cancer treatment decisions. OmiCure’s technology combines a proprietary advanced analytical explainable Artificial Intelligence xAI platform, with a comprehensive knowledgebase of scientific and medical advances. It has the power to analyze clinically relevant cancer biomarkers from DNA, RNA and protein profiles, from both solid and liquid biopsies.

This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile.

OmiCure provides worldwide access to state-of-the-art analyses to cancer centers, oncologists, and physicians, who aim to improve their therapeutic decision making in oncology. The xAI platform processes molecular biology data, including sequencing data from NGS platforms, and turns them into clinical insights.

For more information, visit: www.omicure.com

About CENTRE LEON BERARD anti-cancer center

CLB is one of the leading French Comprehensive Cancer Centres dedicated to excellent medical care, research and education and a member of the Federation of Cancer Centres (UNICANCER), OECI (Organisation of European Cancer Institutes)-certified. Ranked among the top 3 French cancer hospitals in terms of patient recruitment in clinical trials including CLB sponsored ones, CLB is certified by the French National Cancer (INCa) for early phase clinical trials (CLIP2 center).

CLB and its Molecular Tumor Board has a leading position and extensive experience in precision medicine by sponsoring large studies such as PROFILER (NCT01774409; > 4,000 patients included), PROFILER 02 (NCT03163732), MOST plus (NCT02029001) and more recently PLANET (NCT05099068) studies.

Finally, CLB is labelled by INCa since 2011 as an Integrated Cancer Research Site (SIRIC LYriCAN) and is actively involved in translational research with > 500 researchers on-site and 3 research Units including the Cancer Research Centre of Lyon (CRCL, UMR Inserm 1052 – CNRS 5286 – Centre Léon Bérard).

Contact

Tersan Pharmaceuticals Ltd
Marion SOTO
VP business Development
M.soto@tersanpharm.com

The post Tersan Pharmaceuticals Ltd, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients. first appeared on Tersan Pharmaceuticals Ltd.

Anavex Life Sciences and Tersan Pharmaceuticals Ltd present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference

it — Tue, 22 Mar 2022 21:31:38 +0000

Anavex Life Sciences and Tersan Pharmaceuticals Ltd present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference

Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Tersan, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.

Cambridge, Mass. and Paris, France, March 21st, 2022. Tersan Pharmaceuticals Ltd, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference.

MDS-UPDRS Total score improved significantly for patients treated with ANAVEX®2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant, corresponding to a relative improvement of 18.9% over 14 weeks. Balanced and global improvements were observed within all MDS-UPDRS sub-scores Part I-IV.

SIGMAR1 mRNA expression biomarker, previously identified using Tersan’s eXplainable Artificial Intelligence (xAI) KEM® technology, was significantly increased in ANAVEX®2-73 treated patients vs. placebo over the course of treatment (p=0.035). In addition, this biomarker was significantly associated with improvements of MDS-UPDRS scores and cognitive efficacy endpoints CDR system.

Age, certain neurophysiological measures, and high systolic blood pressure at baseline were identified with an increased response for the endpoints.

This finding builds on the KEM® AI-driven precision medicine clinical development platform of ANAVEX®2-73, where the SIGMAR1 mRNA expression biomarker as previously identified as a potential biomarker (Hampel et al, Alzheimer Dement (N Y). 2020; 6(1): e12013) is characterized across multiple indications, including Alzheimer’s Disease and Rett syndrome.

“The reported strong positive biomarker and clinical results in Parkinson’s Disease Dementia, building on previously reported positive results in RETT syndrome and Alzheimer’s disease, further illustrate the power of KEM® Explainable AI to accelerate precision medicine drug development building on in-depth understanding of the intersection between SIGMAR1 molecular pathways and disease biology” said Mohammad Afshar, M.D., Ph.D., Chief Executive Officer of Tersan Pharmaceuticals Ltd.

More information

Poster: ANAVEX®2-73 (blarcamesine): Analysis Of Movement (MDS-UPDRS) And Cognitive (CDR System) Pharmacodynamic Biomarker Outcome Measures of Placebo-Controlled Phase 2 Trial in 132 Parkinson’s Disease Dementia Patients J. Kulisevsky, T. Fadiran, E. Hammond, C. Missling, C. Williams, F. Parmentier, M. Kindermans & M. Afshar. Proceedings of the AD/PD 2022 International Conference on Alzheimer’s & Parkinson’s Diseases and related neurological disorders. Barcelona, Spain, March 15–20, 2022 – click here

ANAVEX’s press release – click here

About Tersan Pharmaceuticals Ltd

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012.

Further information is available at www.tersanpharm.com.

The post Anavex Life Sciences and Tersan Pharmaceuticals Ltd present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference first appeared on Tersan Pharmaceuticals Ltd.

Cyclerion Therapeutics and Tersan Pharmaceuticals Ltd Announce an Artificial Intelligence-driven Precision Medicine Collaboration

it — Wed, 23 Feb 2022 14:10:19 +0000

Cyclerion Therapeutics and Tersan Pharmaceuticals Ltd Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Collaboration to identify patient-selection and pharmacodynamic biomarkers, and optimal endpoints for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment.

Cambridge, Mass. and Paris, France, February 23, 2022 — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Tersan Pharmaceuticals Ltd (Cambridge, MA and Paris, France) today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and neuropsychiatric diseases associated with cognitive impairment.

Tersan Pharmaceuticals Ltd’s proprietary KEM® (Knowledge Extraction and Management) eXplainable Artificial Intelligence (xAI) technology aims at significantly increasing success rates and accelerating clinical development timelines by fully evaluating complex clinical study data, including the discovery of hidden pharmacological and efficacy signals that may be beyond the reach of conventional statistical analyses. This approach enables identification of specific target patient populations, as well as biomarkers of therapeutic response for future clinical studies.

Tersan Pharmaceuticals Ltd and Cyclerion will initially focus on supporting the development of CY6463, Cyclerion’s lead clinical program. The collaboration will analyze data from completed Phase 1 clinical studies of CY6463, including a completed translational pharmacology study in healthy elderly subjects, as well as an ongoing study in Cognitive Impairment Associated with Schizophrenia (CIAS). Insights from these analyses are expected to accelerate and support further clinical development of CY6463.

CY6463 is an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator that is being developed for neurological and neuropsychiatric diseases associated with cognitive impairment. CY6463 was designed to address multiple pathophysiological features of these disorders. Results from initial CY6463 clinical studies have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid. Furthermore, promising impacts on EEG measures, neuroinflammation, and other measures support the current clinical development of CY6463. In addition to the ongoing study in CIAS, studies to evaluate CY6463 safety and signals of clinical activity are also ongoing in participants with Alzheimer’s Disease with vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). Cyclerion expects to obtain clinical results from the MELAS and CIAS studies in Q2 2022 and 2H 2022, respectively. The ADv study initiated patient dosing in January 2022 and enrollment is ongoing.

“Tersan integrates disease biology, mechanism information, and pre/clinical data in their AI platform. This multidimensional machine learning approach, based on Formal Concept Analysis, identifies all possible relationships, the strongest of which may form the basis of drug-specific patient selection and/or surrogate pharmacology/efficacy markers and identify additional indications. We believe that Tersan’s extensive drug development experience in the CNS and the application of this technology to our innovative pipeline may be quite powerful in guiding efficient drug development, and we look forward to a productive collaboration focused on successfully advancing CY6463 for diseases associated with cognitive impairment,” said Andy Busch Ph.D., Chief Scientific Officer of Cyclerion Therapeutics.

“We are eager to apply our pioneering eXplainable AI platform KEM® to support the development of Cyclerion’s promising therapeutic candidates. We believe that our platform has the capacity to help guide the selection of patients who may benefit most from the therapy, by identifying patient-selection biomarkers, and the right measure of therapeutic efficacy, by identifying pharmacodynamic biomarkers, and optimal endpoints for future clinical development. We are excited about the prospect of using our xAI to accelerate the precision medicine development of CY6463 towards effective treatments against devastating neurological and neuropsychiatric diseases” said Mohammad Afshar, M.D., Ph.D., Chief Executive Officer of Tersan Pharmaceuticals Ltd.

Download the press release here

About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463, has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer’s Disease with Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. Further information is available at www.tersanpharm.com.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in Cyclerion’s 2020 Form 10-K filed on February 25, 2021, and subsequent SEC filings including the Form 10-Q filed on April 30, 2021, July 29, 2021 and November 9, 2021. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law.

The post Cyclerion Therapeutics and Tersan Pharmaceuticals Ltd Announce an Artificial Intelligence-driven Precision Medicine Collaboration first appeared on Tersan Pharmaceuticals Ltd.

Tersan appoints pharmaceutical industry drug development veteran

it — Thu, 06 May 2021 10:52:01 +0000

Tersan appoints pharmaceutical industry drug development veteran, Hichem Chakroun, Executive VP Clinical Development, as the company expands Precision Medicine collaborations.

Paris, France and Cambridge, MA, USA. May 6^th 2021. Ariana, a leading eXplainable Artificial Intelligence (AI) drug development company, is delighted to announce the appointment of Dr. Hichem Chakroun as Executive VP, Clinical Development. As EVP, Hichem will apply his industry expertise and experience to help accelerate the strategy of Tersan in the clinical trials setting.

Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas and include the worldwide registration of key products such as Imovane®, Taxotere® and Jevtana®. He has transitioned many assets from research to development and has managed multiple clinical projects up to their regulatory submissions.

Tersan’s growing project pipeline includes CNS, immunology, immuno-oncology and oncology, all areas where Dr Chakroun brings a wealth of experience.

Hichem joins Tersan following four years of exponential growth for the company across multiple therapeutic areas. Tersan’s AI-designed clinical trials, developed in partnership with ANAVEX® (NASDAQ:AVXL), were the first successful genomic Precision Medicine studies in Alzheimer’s disease with confirmed translational applications in Parkinson’s disease and Rett syndrome. A clinical and multi-genomic research collaboration in auto-immune diseases with leading institution Institut Imagine (Paris, France) and Sanofi through the ATRACTion project will pave the way for future innovation in this area. In addition to this project, Tersan has been working with the French pharmaceutical industry and other partners for the establishment, characterization, standardization and the use of cancer models in the development of new drugs and personalized medicine (IMODI).

“Hichem is a highly respected global clinical drug development leader who brings a wealth of experience to the company. His experience will prove invaluable, as we drive through ambitious plans to expand our operations” said Mohammad Afshar, CEO and founder of Ariana. “We are excited to have Hichem’s expertise as we continue on our path at the intersection of AI and drug development”.
Commenting on his new role, Dr. Chakroun said, “I am thrilled to be joining Tersan at such a critical point in their expansion. I am a true believer in their unique and innovative approach to drug development. I admire the work this talented team has done over the past few years which should dramatically reduce the time-to-market for innovative therapies for patients”.

Hichem started his career as a Research Associate, Neurobiology at the French Medical Institute (INSERM) working on depression and Alzheimer’s disease. He later joined Rhône-Poulenc Central Nervous System and then Oncology. Following a successful experience in Global Clinical Development he spent more than 15 years in the exciting area of the Portfolio Management and Project Direction at Aventis then Sanofi, in growing responsibility drug development positions including Director of Development Operations, managing complex projects in a highly multi-cultural environment.

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as FACS), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. Further information is available at www.tersanpharm.com.

The post Tersan appoints pharmaceutical industry drug development veteran first appeared on Tersan Pharmaceuticals Ltd.

Tersan announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi

it — Thu, 06 May 2021 10:49:01 +0000

Tersan Pharmaceuticals Ltd announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies.

Explainable Artificial Intelligence and multi-omic investigations in autoimmune and inflammatory diseases

Paris, France and Cambridge, MA, USA, April 29th, 2020. Tersan® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies.

The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases. Tersan will use its KEM® Explainable Artificial Intelligence technology to identify biomarkers and develop an AI driven therapeutic decision support software.

Coordinated by the Institut Imagine, the €10 million funded 5 years collaboration aims at developing disruptive and transformative approaches in the fields of diagnosis, prognosis and therapies to fight pathologies related to the mechanisms of autoimmunity and inflammation in primary immune deficiencies.

More information about this project can be found below.

https://www.institutimagine.org/en/autoimmune-and-inflammatory-diseases-associated-primary-immune-deficiencies-11-major-healthcare-988

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Explainable Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as FACS), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. Further information is available at www.tersanpharm.com.

The post Tersan announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi first appeared on Tersan Pharmaceuticals Ltd.

Tersan Announces Appointment of Accomplished Business and Strategy Executive, Kia Motesharei to its Board of Directors.

it — Wed, 05 May 2021 06:49:15 +0000

Paris and Boston, October 21^st, 2020. Tersan® Pharma a leading digital health company today announced the appointment of Kia Motesharei, PhD to its board of directors as Senior Vice President of Business Development. Dr. Motesharei joins existing directors Mohammad Afshar, MD, PHD President and CEO, Felix Frueh, PhD, Isabelle Buckle, PhD, Adam Afshar and Daniel Bernier.

Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.

“His significant insights will be invaluable to us as we develop novel partnerships around our Explainable AI Driven Precision Medicine platform across multiple therapeutic areas” said Mohammad Afshar. “On behalf of Tersan and the Board of Directors, I welcome Kia and look forward to drawing upon his strategic, operational and business development judgment.”

Dr. Motesharei is currently Senior Vice President of Business Development & Corporate Strategy with Akcea Therapeutics. Most recently, Kia was Vice President, Global Head Licensing & Business Development, Neurology & Immunology at Merck KGaA. Prior to that, Kia was Vice President of Business Development & Alliance Management at Dyax, Chief Business Officer at the French biotech company Genfit, and Vice President of Corporate Development at ActivX.

Kia has a successful track record of over 100 transactions which include research and strategic alliances, product and technology licensing, distribution, divestitures, and M&A agreements with major pharmaceutical and biotechnology companies in the US, Europe, Japan, China, LATAM, and the Middle East. In addition, he has been involved in a number of financing activities.

Kia received his BA in Chemistry from Colorado College and his PhD in Organic Chemistry from the University of California, Los Angeles. He completed his postdoctoral training at The Scripps Research Institute as an NIH Fellow.

“I am thrilled and look forward to joining the dedicated professionals at Tersan as the company expands the application of its AI technology platform to optimize clinical trial outcomes to enable its partners deliver their therapeutics products to patients more effectively and with higher probability of success and lower risk ” said Dr. Motesharei.

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading digital health Company focused on developing advanced therapeutic decision support systems. Using its KEM® Explainable Artificial Intelligence (XAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and identify the best clinical endpoints, the best responders and the best potential synergistic drugs. Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as FACS), microbiota, Patient Reported Outcomes as well as Real World Evidence data. Combining advanced data analytics with regulatory expertise, Tersan helps translate findings into innovative clinical plans. With a growing number of successful therapeutic development applications, KEM® is the only FDA-reviewed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology treatment selection system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. Further information is available at www.tersanpharm.com.

The post Tersan Announces Appointment of Accomplished Business and Strategy Executive, Kia Motesharei to its Board of Directors. first appeared on Tersan Pharmaceuticals Ltd.

Tersan Pharmaceuticals Ltd joins the Healthcare Data Institute

it — Mon, 25 Jul 2016 22:11:00 +0000

Tersan is pleased to announce that the company has joined the Healthcare Data Institute.

The Healthcare Data Institute is the first international think tank dedicated to Big Data in the health sector. An Orange Healthcare initiative, the Healthcare Data Institute was launched in partnership with other companies representative of the Big Data health ecosystem: government and regulatory agencies, pharmaceutical companies, leading figures from the medical world, start-ups and insurance companies.

In joining the group of leading healthcare sector research companies, Tersan’s CEO Dr Afshar declared:

“I am honored to contribute to thought provoking sessions with HDI on the integration of decision making tools as a standard part of treatment in personalized medicine. Tersan’s 12+ year experience in developing and implementing such tools is part of the revolution presently occurring in the healthcare sector. We will definitely get to the point where clinicians will be able to routinely choose the right drug for each patient – and HDI is the perfect platform to help advance this strategy”.

The post Tersan Pharmaceuticals Ltd joins the Healthcare Data Institute first appeared on Tersan Pharmaceuticals Ltd.

Pharma Boardroom interview with Mohammad Afshar

it — Tue, 12 Jul 2016 22:24:00 +0000

Interview with Mohammad Afshar – CEO, Tersan Pharmaceuticals Ltd, France, 12 July 2016

Mohammad Afshar, CEO of Tersan Pharmaceuticals Ltd, shares his insights on the importance of decision support tools, big data’s impact on the healthcare industry, and the need to translate this data into the production of real products. He also discusses the challenges he faced as an entrepreneur in France and his goals for the future.

Read the full PharmaBoardroom interview with Mohammad online.

Links: Read online

The post Pharma Boardroom interview with Mohammad Afshar first appeared on Tersan Pharmaceuticals Ltd.

Tersan Science Day (Paris | May 9)

it — Mon, 09 May 2016 22:40:00 +0000

Tersan hosted their regular Science Day this week – a 1-day symposium in Paris on advances in machine learning and artificial intelligence, chaired by Dr Jean Sallantin, Director of Research at the CNRS LIRMM (Laboratoire d’Informatique, de Robotique et de Micro-électronique de Montpellier) and Scientific Advisor to Tersan.

As ever, this was a stimulating day comprising a series of short presentations from Tersan data scientists and leading academic practictioners, and provided an excellent opportunity for intensive discussion and sharing of ideas around all aspects of unsupervised and supervised learning. Topics covered a diverse range of industrial use cases drawn from the extensive Tersan project portfolio (including predictive algorithm development for personalized medicine, multi-marker biomarker signature characterization, and analysis of rare events in large Real World Evidence data sets), and methodology developments and future trends in the field of Deep Learning.

The post Tersan Science Day (Paris | May 9) first appeared on Tersan Pharmaceuticals Ltd.

NoFinishLine Paris 2016 (Paris | April 13)

it — Wed, 13 Apr 2016 22:42:00 +0000

The Tersan Running Team are pleased to participate in the popular NoFinishLine Paris 2016 charitable fun run event in support of sick and homeless children.

Tersan Running Team at NoFinishLine Paris 2016

(Left to right): Sébastien Vaucouleur, Isabelle Chaduteau, Dan Manak, Mohammad Afshar, Yannic Tognetti, Frédéric Parmentier (11254), David Morley, Vincent Récamier, Julie Miralves, Ariane Odjo, Mariana Kuras

The post NoFinishLine Paris 2016 (Paris | April 13) first appeared on Tersan Pharmaceuticals Ltd.